<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122715">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932372</url>
  </required_header>
  <id_info>
    <org_study_id>A3921194</org_study_id>
    <nct_id>NCT01932372</nct_id>
  </id_info>
  <brief_title>Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis</brief_title>
  <official_title>Tofacitinib (Xeljanz Tablets 5 mg) Long Term Special Investigation for Rheumatoid Arthritis (Regulatory Post Marketing Commitment Plan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Japan: Foundation for Biomedical Research and Innovation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Surveillance is to verify the following subject matters concerning
      Tofacitinib (Xeljanz) under general practice.

      1)    Occurrence of adverse reactions, factors that may potentially affect safety and
      efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and
      efficacy

      Occurrences of malignant tumors and serious infections will be compared with a control
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes the Xeljanz or Standard of Care for
      rheumatoid arthritis should be registered consecutively until the number of subjects reaches
      target number in order to extract patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Disease Activity Score Based on 28-joints Count (DAS28)</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-Related Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.  An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tofacitinib (Xeljanz)</arm_group_label>
    <description>Tablets 5 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <description>Standard of Care for Rheumatoid Arthritis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib (Xeljanz)</intervention_name>
    <description>5 mg Tablet BID</description>
    <arm_group_label>Tofacitinib (Xeljanz)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc</intervention_name>
    <description>Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with moderately to severely active rheumatoid arthritis who have had an
        inadequate response or intolerance to over 8 mg Methotrexate for 3 months treatment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients receiving Tofacitinib (Xeljanz)

        Exclusion Criteria:

        Not Applicable
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921194&amp;StudyName=Tofacitinib%20%28Xeljanz%29%20Special%20Investigation%20for%20Rheumatoid%20Arthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Good Post Marketing Study Practice</keyword>
  <keyword>Tofacitinib</keyword>
  <keyword>Xeljanz</keyword>
  <keyword>Regulatory Post Marketing Commitment Plan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
